Premium
Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension
Author(s) -
Skurk T.,
Lee Y.M.,
NicutaRölfs T.O.,
Haastert B.,
Wirth A.,
Hauner H.
Publication year - 2004
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2004.00316.x
Subject(s) - candesartan , fibrinolysis , medicine , endocrinology , angiotensin ii , plasminogen activator , blood pressure , essential hypertension , plasminogen activator inhibitor 1 , tissue plasminogen activator
Aim: Impaired fibrinolysis is frequently observed in patients with the metabolic syndrome. Aim of the study was to examine the short‐term effect of angiotensin II receptor blockade on the fibrinolytic system. Methods: Seventy‐four patients with mild hypertension were randomly assigned to a 7‐day treatment period with either 16 mg candesartan cilexetil or placebo. Several variables of the fibrinolytic system such as plasminogen activator inhibitor‐1 (PAI‐1) antigen and activity, tissue plasminogen activator (t‐PA) antigen and activity as well as circulating t‐PA/PAI‐1 complexes were determined. Results: At baseline, the body mass index but not blood pressure was positively associated with PAI‐1 antigen (r = 0.314, p < 0.01) and PAI‐1 activity (r = 0.425, p < 0.01) but negatively with t‐PA activity (r = −0.187, p < 0.05). A 7‐day treatment with 16 mg candesartan cilexetil resulted in a significant greater reduction of diastolic blood pressure (−10.3 ± 10.8 mmHg vs.−5.8 ± 8.5 mmHg, p = 0.03). However, there was no significant effect of candesartan on all parameters of the fibrinolytic system under investigation, i.e. circulating PAI‐1 antigen, PAI‐1 activity, t‐PA antigen, t‐PA activity and t‐PA/PAI‐1 complexes. Furthermore, candesartan did not affect the characteristic circadian pattern of the variables of the fibrinolytic system. Conclusion: We conclude that short‐term blockade of the angiotensin II receptor subtype 1 with candesartan does not have an impact on fibrinolysis in patients with mild hypertension.